JPMorgan Chase & Co. Cuts Humana (NYSE:HUM) Price Target to $575.00

Humana (NYSE:HUMGet Free Report) had its price objective dropped by research analysts at JPMorgan Chase & Co. from $593.00 to $575.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 13.90% from the company’s previous close.

A number of other equities research analysts have also issued reports on HUM. Royal Bank of Canada upped their target price on shares of Humana from $594.00 to $599.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Humana from $468.00 to $628.00 and gave the stock a “buy” rating in a research note on Monday, August 7th. Sanford C. Bernstein decreased their target price on shares of Humana from $599.00 to $579.00 in a report on Tuesday, October 10th. StockNews.com upgraded shares of Humana from a “buy” rating to a “strong-buy” rating in a report on Friday, November 3rd. Finally, TD Cowen decreased their price objective on Humana from $616.00 to $613.00 and set an “outperform” rating on the stock in a report on Tuesday, August 15th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humana has an average rating of “Moderate Buy” and a consensus price target of $590.28.

View Our Latest Analysis on HUM

Humana Price Performance

HUM traded down $8.09 during midday trading on Friday, hitting $504.82. 305,774 shares of the company traded hands, compared to its average volume of 1,142,177. The company has a market capitalization of $62.15 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.33 and a beta of 0.61. The business has a 50 day simple moving average of $496.41 and a two-hundred day simple moving average of $486.16. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.56. Humana has a 52-week low of $423.29 and a 52-week high of $558.04.

Humana (NYSE:HUMGet Free Report) last posted its quarterly earnings data on Wednesday, November 1st. The insurance provider reported $7.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.15 by $0.63. The company had revenue of $26.42 billion for the quarter, compared to analysts’ expectations of $25.57 billion. Humana had a return on equity of 21.03% and a net margin of 2.95%. Humana’s revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.88 EPS. On average, equities analysts forecast that Humana will post 28.28 earnings per share for the current fiscal year.

Institutional Trading of Humana

A number of large investors have recently bought and sold shares of HUM. Sunbelt Securities Inc. purchased a new position in Humana during the first quarter worth about $28,000. WFA of San Diego LLC acquired a new position in Humana during the second quarter worth about $29,000. Gradient Investments LLC increased its holdings in Humana by 50.0% in the second quarter. Gradient Investments LLC now owns 69 shares of the insurance provider’s stock valued at $31,000 after buying an additional 23 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Humana by 81.0% during the 2nd quarter. Larson Financial Group LLC now owns 76 shares of the insurance provider’s stock valued at $34,000 after acquiring an additional 34 shares during the period. Finally, Baystate Wealth Management LLC increased its stake in Humana by 84.1% in the 2nd quarter. Baystate Wealth Management LLC now owns 81 shares of the insurance provider’s stock valued at $37,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 91.86% of the company’s stock.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Stories

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.